Theodore R. Schroeder - 06 Jan 2023 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
NBRVF
Transactions as of
06 Jan 2023
Transactions value $
-$14
Form type
4
Date filed
10 Jan 2023, 16:56
Previous filing
04 Jan 2023
Next filing
31 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRVF Ordinary Shares Tax liability -$14 -11 -0.09% $1.30 12.4K 06 Jan 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.